Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?

被引:90
作者
Chadha, Awalpreet S. [1 ]
Liu, Guan [1 ]
Chen, Hsiang-Chun [2 ]
Das, Prajnan [1 ]
Minsky, Bruce D. [1 ]
Mahmood, Usama [1 ]
Delclos, Marc E. [1 ]
Suh, Yelin [3 ]
Sawakuchi, Gabriel O. [3 ,6 ]
Beddar, Sam [3 ]
Katz, Matthew H. [4 ]
Fleming, Jason B. [4 ]
Javle, Milind M. [5 ]
Varadhachary, Gauri R. [5 ]
Wolff, Robert A. [5 ]
Crane, Christopher H. [1 ]
Wang, Xuemei [2 ]
Thames, Howard [1 ]
Krishnan, Sunil [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[6] Univ Texas, Grad Sch Biomed Sci, Houston, TX USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 97卷 / 02期
关键词
CELL LUNG-CANCER; TREATMENT-RELATED LYMPHOPENIA; FAS RECEPTORS; IMMUNOTHERAPY; RADIOTHERAPY; SURVIVAL; ASSOCIATION; LYMPHOCYTES; CARCINOMA; VOLUME;
D O I
10.1016/j.ijrobp.2016.10.046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether severity of lymphopenia is dependent on radiation dose and fractional volume of spleen irradiated unintentionally during definitive chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC). Methods: 177 patients with LAPC received induction chemotherapy (mainly gemcitabine-based regimens) followed by CRT (median 50.4 Gy with concurrent capecitabine) from January 2006 to December 2012. Absolute lymphocyte count (ALC) was recorded at baseline, before CRT, and 2 to 10 weeks after CRT. Splenic dose-volume histogram (DVH) parameters were reported as mean splenic dose (MSD) and percentage of splenic volume receiving at least 5- (V5), 10- (V10), 15- (V15), and 20-Gy (V20) dose. Overall survival (OS) was analyzed with use of the Cox model, and development of post-CRT severe lymphopenia (ALC < 0.5 K/UL) was assessed by multivariate logistic regression with use of baseline and treatment factors. Results: The median post-CRT ALC (0.68 K/UL; range, 0.13-2.72) was significantly lower than both baseline ALC (1.42 K/UL; range, 0.34-3.97; P<.0001) and pre-CRT ALC (1.32 K/UL, range 0.36-4.82; P<.0001). Post-CRT ALC <0.5 K/UL was associated with inferior OS on univariate analysis (median, 11.1 vs 15.3 months; P = .01) and multivariate analysis (hazard ratio = 1.66, P = .01). MSD (9.8 vs 6 Gy, P = .03), median V10 (32.6 vs 16%, P = .04), V15 (23.2 vs 9.5%, P = .03), and V20 (15.4 vs 4.6%, P = .02) were significantly higher in patients with severe lymphopenia than in those without. On multivariate analysis, postinduction lymphopenia (P<.001; odds ratio [OR] = 5.25) and MSD (P = .002; OR = 3.42) were independent predictors for the development of severe post-CRT lymphopenia. Conclusion: Severe post-CRT lymphopenia is an independent predictor of poor OS in LAPC patients receiving CRT. Higher splenic doses increase the risk for the development of severe post-CRT lymphopenia. When clinically indicated, assessment of splenic DVHs before the acceptance of treatment plans may minimize the risk of severe post-CRT lymphopenia. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 46 条
  • [1] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [2] The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas
    Balmanoukian, Ani
    Ye, Xiaobu
    Herman, Joseph
    Laheru, Daniel
    Grossman, Stuart A.
    [J]. CANCER INVESTIGATION, 2012, 30 (08) : 571 - 576
  • [3] Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
    Bellone, G
    Turletti, A
    Artusio, E
    Mareschi, K
    Carbone, A
    Tibaudi, D
    Robecchi, A
    Emanuelli, G
    Rodeck, U
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) : 537 - 547
  • [4] Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer
    Campian, Jian L.
    Sarai, Guneet
    Ye, Xiaobu
    Marur, Shanthi
    Grossman, Stuart A.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (12): : 1747 - 1753
  • [5] Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer
    Campian, Jian L.
    Ye, Xiaobu
    Brock, Malcolm
    Grossman, Stuart A.
    [J]. CANCER INVESTIGATION, 2013, 31 (03) : 183 - 188
  • [6] Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer
    Chadha, Awalpreet S.
    Kocak-Uzel, Esengul
    Das, Prajnan
    Minsky, Bruce D.
    Delclos, Marc E.
    Mahmood, Usama
    Guha, Sushovan
    Ahmad, Mediha
    Varadhachary, Gauri R.
    Javle, Milind
    Katz, Matthew H.
    Fleming, Jason B.
    Wolff, Robert A.
    Crane, Christopher H.
    Krishnan, Sunil
    [J]. ACTA ONCOLOGICA, 2015, 54 (07) : 971 - 978
  • [7] Silencing the Killers: Paracrine Immune Suppression in Pancreatic Cancer
    Cox, Adrienne D.
    Olive, Kenneth P.
    [J]. CANCER CELL, 2012, 21 (06) : 715 - 716
  • [8] COX DR, 1972, J R STAT SOC B, V34, P187
  • [9] NORMAL TISSUE COMPLICATION PROBABILITY ESTIMATION BY THE LYMAN-KUTCHER-BURMAN METHOD DOES NOT ACCURATELY PREDICT SPINAL CORD TOLERANCE TO STEREOTACTIC RADIOSURGERY
    Daly, Megan E.
    Luxton, Gary
    Choi, Clara Y. H.
    Gibbs, Iris C.
    Chang, Steven D.
    Adler, John R.
    Soltys, Scott G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05): : 2025 - 2032
  • [10] Role of Local Radiation Therapy in Cancer Immunotherapy
    Demaria, Sandra
    Golden, Encouse B.
    Formenti, Silvia C.
    [J]. JAMA ONCOLOGY, 2015, 1 (09) : 1325 - 1332